<DOC>
	<DOCNO>NCT00002845</DOCNO>
	<brief_summary>RATIONALE : Interleukin-2 may stimulate person 's white blood cell kill melanoma cell . PURPOSE : Phase II trial study effectiveness interleukin-2 treating patient metastatic melanoma .</brief_summary>
	<brief_title>Interleukin-2 Treating Patients With Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate response survival rate patient metastatic melanoma follow induction high-dose maintenance low-dose interleukin-2 . II . Assess toxicity regimen . OUTLINE : All patient receive high-dose interleukin-2 24 hour , follow low-dose interleukin-2 4 day absence toxicity . Patients receive second cycle begin 9-13 day completion first cycle , response assess approximately 2 month initiate therapy . Patients stable respond disease receive second course ; continue response may receive additional course provide toxicity limit . Patients follow survival . PROJECTED ACCRUAL : 20 patient enter .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven melanoma metastatic No tumor replacement 25 % liver CT MRI No involvement CNS major nerve Measurable disease require PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 80 % 100 % Life expectancy : More 3 month Hematopoietic : No coagulopathy ( i.e. , platelet le 80,000 ) Hepatic : Bilirubin normal Renal : Creatinine normal Cardiovascular : No abnormal cardiac stress test patient 50 year age possible cardiac disease suggest history , physical exam , EKG Pulmonary : FEV1 VC great 65 % predict patient significant smoke history suspect pulmonary disease history , physical exam , xray Other : No site ongoing bleed No systemic infection No HIV antibody No HBsAg No requirement steroids No psychiatric disease precludes inform consent protocol treatment No second malignancy except : Basal cell skin carcinoma Carcinoma situ cervix No pregnant nursing woman Negative pregnancy test require fertile woman Effective contraception require fertile woman PRIOR CONCURRENT THERAPY : No prior interleukin2 At least 28 day since treatment melanoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2000</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>